Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1\/M1<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 17, 2026 (HealthDay News) — Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)\/computed tomography (CT)-guided salvage radiotherapy is associated with favorable outcomes after radical prostatectomy in patients with prostate cancer, according to a study published in the February issue of the Journal of the National Comprehensive Cancer Network<\/em>.<\/p>\n John Nikitas, M.D., from the University of California, Los Angeles, and colleagues conducted a retrospective analysis of five prospective PSMA PET\/CT studies to examine the impact of guided management on clinical outcomes following salvage radiotherapy.<\/p>\n Overall, 113 patients met the inclusion criteria; patients were followed for a median of 59.4 months. The researchers found that 19, 32, 16, and 46 patients were staged as TrN0M0, N1M0, M1, and T0N0M0 on PSMA-PET\/CT (16.8, 28.3, 14.2, and 40.7 percent), respectively. Androgen deprivation therapy (ADT) was administered to 67.3 percent of patients, and whole-pelvis radiotherapy (WPRT) was administered to 55.8 percent. Overall, 50.4 percent of patients had disease progression. Median progression-free survival (PFS) and median freedom from distant progression were 49.2 months and 76.4 months, respectively. The rate of five-year overall survival was 97.1 percent. Among patients staged as TrN0M0, WPRT was significantly associated with improved PFS (adjusted hazard ratio, 0.12); in patients staged as N1\/M1, ADT was significantly associated with improved PFS (adjusted hazard ratio, 0.37).<\/p>\n “PSMA PET\/CT scans allow us to see exactly where cancer is and tailor treatment accordingly,” senior author Jeremie Calais, M.D., Ph.D., also from the University of California, Los Angeles, said in a statement. “Patients can get the therapy they need while avoiding unnecessary side effects, and even those with no visible disease can do very well with standard radiation.”<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n